Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET
Company Participants
Margaret Horn - Chief Operating Officer
Mark Goldsmith - Chairman, President and Chief Executive Officer
Steve Kelsey - President of Research and Development
Jack Anders - Chief Financial Officer
Conference Call Participants
Faisal Khurshid - SVB Securities
Michael Schmidt - Guggenheim Partners
Marc Frahm - Cowen and Company, LLC
Eric Joseph - JPMorgan Chase & Co.
Benjamin Burnett - Stifel Financial Corp.
Alec Stranahan - Bank of America Merrill Lynch
Ami Fadia - Needham & Company
Jay Olson - Oppenheimer & Co.
Operator
Good day, and thank you for standing by. Welcome to the Revolution Medicines Q4 Year-End 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Peg Horn, Chief Operating Officer. Please go ahead.
Margaret Horn
Thank you, and welcome, everyone, to the fourth quarter and full-year 2022 earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicines Chairman and Chief Executive Officer; Dr. Steve Kelsey, the Company's President of Research and Development; and Jack Anders, our Chief Financial Officer.
As we begin, I would like to note that our presentation will include statements regarding the current beliefs of the Company with respect to our business that constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are subject to a number of assumptions, risks and uncertainties. Actual results may differ materially from these statements and except as required by law, the Company undertakes no obligation to revise or update any forward-looking statements. I encourage you to review the legal disclaimer slide of our corporate presentation or the earnings press release as well as all of the Company's filings with the SEC concerning these and other matters.
During this presentation, we will be referring to a number of slides from our corporate presentation. The entire presentation was posted to our website immediately prior to this call.
With that, I will turn the call over to Dr. Mark Goldsmith, Revolution Medicines Chairman and Chief Executive Officer. Mark?
Mark Goldsmith
Good afternoon, and thank you for joining us. Today, I'll provide an update on our company progress. Steve Kelsey will provide additional information about our RMC-6236 clinical program, and Jack Anders will provide highlights of our financial results.